scholarly article | Q13442814 |
P356 | DOI | 10.1097/MIB.0000000000001074 |
P698 | PubMed publication ID | 28328624 |
P50 | author | Christopher Ma | Q49218919 |
Vivian W. Huang | Q53196309 | ||
Subrata Ghosh | Q59832001 | ||
Remo Panaccione | Q92078930 | ||
P2093 | author name string | Brendan P Halloran | |
Richard N Fedorak | |||
Gilaad G Kaplan | |||
Yvette Leung | |||
Cynthia H Seow | |||
Karen Wong | |||
Shane M Devlin | |||
Levinus A Dieleman | |||
Kerri L Novak | |||
Karen I Kroeker | |||
Nathan Stern | |||
Philip K Blustein | |||
P2860 | cites work | Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 |
Ustekinumab in Crohn's disease: evidence to date and place in therapy | Q28073787 | ||
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
Certolizumab pegol for the treatment of Crohn's disease | Q28236746 | ||
A simple index of Crohn's-disease activity | Q28259898 | ||
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene | Q28270603 | ||
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease | Q30054715 | ||
Radiographic imaging of inflammatory bowel disease | Q34139421 | ||
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial | Q34574245 | ||
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications | Q36477912 | ||
Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy | Q37871625 | ||
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. | Q38572827 | ||
The global burden of IBD: from 2015 to 2025. | Q38577572 | ||
Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab | Q38692257 | ||
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience | Q39164487 | ||
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. | Q40472089 | ||
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management | Q40994357 | ||
Ustekinumab induction and maintenance therapy in refractory Crohn's disease | Q42514321 | ||
Development of the Crohn's disease digestive damage score, the Lémann score | Q42759984 | ||
Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. | Q45200648 | ||
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. | Q50237402 | ||
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. | Q53540951 | ||
Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis | Q57910344 | ||
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study | Q59120257 | ||
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response | Q59120277 | ||
P433 | issue | 5 | |
P921 | main subject | Crohn's disease | Q1472 |
P304 | page(s) | 833-839 | |
P577 | publication date | 2017-05-01 | |
P1433 | published in | Inflammatory Bowel Diseases | Q15749161 |
P1476 | title | Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study | |
P478 | volume | 23 |
Q92859154 | Biologic therapies for Crohn's disease: optimising the old and maximising the new |
Q49218809 | Clinical utility of ustekinumab in Crohn's disease. |
Q90055639 | Early real-world effectiveness of ustekinumab for Crohn's disease |
Q48336044 | Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response? |
Q57788239 | Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease |
Q50012048 | Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease |
Q90656440 | Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study |
Q53075985 | Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series. |
Q92895315 | Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study |
Q93184539 | Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease |
Search more.